MiscellaneousUsefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension†
Section snippets
Methods
We studied patients in the Pulmonary Hypertension Connection (PHC) registry, which was initiated in March 2004 and has been described in detail previously.6 For the purposes of the present study, we evaluated only patients entered into the PHC registry prospectively (all patients were evaluated at the University of Chicago Medical Center).
In the PHC registry, only 2 investigators with expertise in data management and understanding of clinical care of patients with PH entered the data. Neither
Results
Of the 162 study patients, 78% were women, and 62% had World Health Organization category I PH (pulmonary arterial hypertension). The mean age was 53 ± 15 years. Overall, patients in the study cohort had severe PH (right atrial pressure 11 ± 7 mm Hg, mean pulmonary artery pressure 48 ± 13 mm Hg, cardiac index 2.5 ± 1.0 L/min/m2, and pulmonary vascular resistance 9.6 ± 6.2 Wood units) and poor functional status (87% had World Health Organization functional class III or IV symptoms). The mean RDW
Discussion
In a prospective study of 162 patients, we found that increased RDW was independently associated with increased mortality in PH. Our results in patients with PH and right-sided heart failure are complementary to recent data that have demonstrated the prognostic utility of RDW in chronic left-sided heart failure, in patients with coronary artery disease, and in unselected patients who undergo coronary angiography.4, 5, 8 Unlike these other studies, RDW values in our study were higher (highest
References (16)
- et al.
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
J Am Coll Cardiol
(2007) - et al.
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension
Chest
(2006) - et al.
Anemia as a risk factor and therapeutic target in heart failure
J Am Coll Cardiol
(2004) - et al.
Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure
Am J Cardiol
(2003) - et al.
The Seattle Heart Failure Model: prediction of survival in heart failure
Circulation
(2006) - et al.
Predictors of mortality and morbidity in patients with chronic heart failure
Eur Heart J
(2006) - et al.
Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease
Circulation
(2008)
Cited by (214)
An optimized machine learning method for predicting wogonin therapy for the treatment of pulmonary hypertension
2023, Computers in Biology and MedicineA new hematologic predictor of major adverse events after cardiac surgery: red cell distribution width to lymphocyte ratio
2023, Anesthesia and Pain Medicine
- †
Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.